Study guide
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending
Board Certified Specialist in Renal Nutrition CSR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Kidney Disease Foundations
1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk
2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment
2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry
3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools
3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss
4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History
4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment
5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality
5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment
6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning
6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances
7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients
7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy
8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy
8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients
9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD
10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support
10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support
11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities
11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories
13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics
13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence
14 Chapter 14: Domain 2 — Care Coordination, Communication & Education
14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support
15 Chapter 15: Domain 3 — Regulations & Quality Management
15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool
16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending
Key Takeaways Explain This Topic AI
The CMS plan-of-care condition requires albumin, body weight and hemoglobin to be measured at least monthly, and hemodialysis adequacy to be assessed at least monthly (PD at least every 4 months).
The CMS survey tool lists calcium and phosphorus monthly, intact PTH every 3 months, and phosphorus of 3.5–5.5 mg/dL; KDIGO 2017 advises lowering elevated phosphate toward the normal range.
Corrected calcium = measured calcium + 0.8 × (4.0 − albumin); KDIGO no longer recommends the calcium-phosphorus product, which was a KDOQI 2003 target (below 55 mg²/dL²).
In dialysis, KDIGO suggests keeping intact PTH at about 2–9 times the assay's upper limit of normal and acting on trends rather than single values.
The CMS survey tool lists albumin of at least 4.0 g/dL by bromocresol green, or the lab's normal range when bromocresol purple (which reads lower) is used.
Last updated: September 2026
Why laboratory surveillance matters
In advanced CKD and on dialysis, the kidneys no longer regulate potassium, phosphorus, acid–base balance or nitrogen waste, so routine labs stand in for the missing physiology. For the renal dietitian, the monthly panel is the main monitoring and evaluation tool in the Nutrition Care Process. Three sources set the rules: what the Conditions for Coverage (CfC) require, what the CMS Measures Assessment Tool (MAT) tells surveyors to look for, and what current KDOQI and KDIGO guidelines recommend.
What is required, and how often
- Test Minimum frequency Source
- Serum albumin At least monthly CfC plan of care, 42 CFR 494.90(a)(2)
- Body weight At least monthly (every treatment in practice) CfC 494.90(a)(2); KDOQI 2020 1.1.5
- Hemoglobin or hematocrit At least monthly CfC 494.90(a)(4)
- HD adequacy (delivered Kt/V or equivalent) At least monthly CfC 494.80(c)(1)
PD adequacy (weekly Kt/V or equivalent) At least every 4 months (MAT: also in the first month) CfC 494.80(c)(2)
- Calcium and phosphorus Monthly MAT; KDIGO 2017 suggests every 1–3 months in G5D
- Intact PTH Every 3 months MAT; KDIGO 2017 suggests every 3–6 months in G5D
- Alkaline phosphatase At least every 12 months, more often if PTH is high KDIGO 2017 (G4–G5D)
- Ferritin and TSAT Every 1–3 months on HD; every 3 months on PD or without dialysis KDIGO 2026 anemia
- 25-hydroxyvitamin D Baseline, then repeat based on values and treatment KDIGO 2017
- Potassium, bicarbonate, BUN, creatinine, glucose Monthly panel Standard practice
- HbA1c (with diabetes) Commonly every 3 months; interpret with caution KDIGO 2022 diabetes
- Lipid profile At baseline; routine follow-up not required for most patients KDIGO 2013 lipids
- Aluminum When clinically indicated MAT and KDIGO 2017
Surveyors do not cite a facility because one patient's value is out of range. They cite it when the IDT fails to recognize and act on out-of-range outcomes (MAT, plan-of-care section).
Targets and where they come from
- Parameter Target or threshold Source and notes
- Pre-dialysis potassium Keep in the normal range; many units use 3.5–5.5 mEq/L KDOQI 2020 6.4.1 (OPINION)
Phosphorus (dialysis) 3.5–5.5 mg/dL (survey tool); lower elevated values toward normal MAT; KDIGO 2017; KDOQI 2020 6.3.1 (normal range, 1B)
Phosphorus (non-dialysis CKD) Normal lab range (about 2.5–4.5 mg/dL) KDOQI 2020; KDIGO 2017
Calcium Avoid hypercalcemia; survey tool: uncorrected calcium in the lab's normal range or below 10.2 mg/dL (3-month rolling average) KDIGO 2017; MAT
Intact PTH (G5D) About 2–9 times the assay upper limit; act on trends KDIGO 2017
Bicarbonate KDOQI: 24–26 mmol/L (OPINION); KDIGO 2024: consider treatment below about 18 mmol/L, not above normal Sources differ
Albumin Survey tool: at least 4.0 g/dL by BCG, or lab normal by BCP; ISRNM PEW criterion below 3.8 g/dL by BCG MAT; ISRNM 2008
Hemoglobin on ESA Keep below 11.5 g/dL during maintenance; consider starting an ESA at 9.0–10.0 g/dL or lower in dialysis KDIGO 2026; FDA labeling warns against targeting above 11 g/dL
Ferritin and TSAT (HD) Start iron when ferritin is 500 ng/mL or less and TSAT 30% or less; hold routine iron when ferritin is above 700 ng/mL or TSAT 40% or higher KDIGO 2026
HbA1c (diabetes) Individualized, from below 6.5% to below 8.0%; unreliable in advanced CKD and dialysis KDIGO 2022
Correcting calcium for albumin
About 40–45% of serum calcium is bound to albumin, so low albumin makes measured total calcium look low. The Payne formula estimates corrected calcium:
Corrected Calcium (mg/dL) = Measured Calcium (mg/dL) + 0.8 × [ 4.0 − Albumin (g/dL) ] \text{Corrected Calcium (mg/dL)} = \text{Measured Calcium (mg/dL)} + 0.8 \times [4.0 - \text{Albumin (g/dL)}] Corrected Calcium (mg/dL) = Measured Calcium (mg/dL) + 0.8 × [ 4.0 − Albumin (g/dL) ]
Correction formulas often misclassify calcium status in dialysis patients. Measure ionized calcium when the answer matters, for example with severe hypoalbuminemia, acid–base disturbance, or symptoms. The ESRD QIP and the survey tool use uncorrected total calcium to avoid formula differences.
Why the calcium × phosphorus product was dropped
The KDOQI 2003 bone guideline recommended keeping the calcium × phosphorus product below 55 mg²/dL² . KDIGO (2009, and again in 2017) stopped recommending it, because the product adds little beyond the separate calcium and phosphorus values and can hide which one is abnormal. Current practice treats phosphorus toward normal and avoids hypercalcemia as separate goals. You may still see the product on older materials and questions, so know the number, but reason with the components.
Reading PTH
Intact PTH assays differ, so KDIGO expresses the dialysis target as a multiple of the upper limit of normal (about 2–9 times) . Rising trends toward the upper end call for attention to phosphorus, 25(OH)D, calcium and PTH-lowering drugs. Values persistently below about 2 times the upper limit, especially with low alkaline phosphatase, suggest adynamic bone disease from over-suppression by calcium loading, active vitamin D or calcimimetics.
Albumin: the assay matters
Bromocresol green (BCG) also binds some globulins and reads higher than bromocresol purple (BCP) , which is more specific. The difference is often several tenths of a g/dL in dialysis patients. Interpret albumin against the method your lab uses. The ISRNM PEW criterion (below 3.8 g/dL) and the survey tool's 4.0 g/dL value refer to BCG. KDOQI 2020 recognizes albumin as a strong predictor of hospitalization and death in maintenance HD (statement 1.2.2, grade 1A), but it cautions that albumin, prealbumin and nPCR are influenced by non-nutritional factors such as inflammation and should not be read in isolation (1.2.1).
Trends versus isolated values
Pattern Likely explanation Nutrition action
Sudden potassium spike (e.g., 4.6 to 6.3 mEq/L) Dietary excess, a new drug, GI bleeding, acidosis, constipation, a missed treatment, or a hemolyzed sample Repeat if hemolysis is suspected; review 72-hour intake, drugs, bowel habits and the dialysate bath
Gradual potassium rise over months Loss of residual function, new RAAS blockade, chronic constipation Adjust the diet plan; discuss a binder or bath change with the team
Sudden albumin drop (e.g., 4.1 to 3.1 g/dL) Inflammation or infection, such as an access infection or pneumonia Look for infection first; do not simply add protein
Slow albumin decline over 6 months Progressive PEW, poor intake or inadequate dialysis Full reassessment: NFPE, intake, nPCR; supplements
- High phosphorus with low nPCR Additive-rich processed foods Additive education; protect protein intake
- Low phosphorus with low nPCR Starvation or binder overdose Reduce binders; nutrition support
- Draw timing and rebound
Draw monthly panels before dialysis , before heparin or saline.
Post-dialysis samples are hemoconcentrated for large molecules (albumin, hemoglobin) and reflect urea removal.
Post-dialysis urea rebound (BUN rising as urea moves out of cells and poorly perfused tissues) is largely complete within 30–60 minutes. Adequacy sampling uses standardized slow-flow or stop-dialysate-flow techniques (section 13.1).
Putting it together
For each monthly review, the dietitian should: (1) compare values with the right target and its source; (2) look at the trend across at least three months; (3) consider non-diet causes (drugs, dialysis dose, inflammation, sampling); (4) choose one or two priority problems for the PES statements; and (5) record the plan and the recheck date in the plan of care.